Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Las Vegas Sands Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Las Vegas Sands Corp. trades at $45.76 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is far larger — about 3.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LVS | |
|---|---|---|
Market Cap | $9.43B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $69.49 |
52-Week Low | $241.71 | $44.78 |
Enterprise Value | $9.18B | $41.33B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.
The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
